Total Funding
92
82
Total FundingPost-IPO Equity raised
Growth Score
5 pts
Heat Score
21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
17863
Alligator Bioscience develops antibody-based immunotherapies for the treatment of cancer by using its protein optimization technology FIND®.
- Johan Gileus: CFOPast Role: InDex Pharmaceuticals, Deputy CEO/CFO
- Malin Carlsson: Executive Vice President and Chief Operating Officer
About the Company
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016.
Alligator uses
its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.
